Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib drug-drug interaction study with midazolam and tolbutamide in patients with tumors
NL-OMON55479Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pexidartinib in tenosynovial giant cell tumor (TGCT), melanoma, gastrointestinal stromal tumor (GIST) and 1 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Midazolam pharmacokinetics and Tolbutamide pharmacokinetics. Started Aug 2018; status: active, not recruiting.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)melanomagastrointestinal stromal tumor (GIST)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON55479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55479.